Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. - Wikidata - wikimedia - TriplyDB

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

http://www.wikidata.org/entity/Q34284225

about

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.Conditioning regimens for hematopoietic cell transplantation: one size does not fit all Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study Current status of allogeneic hematopoietic cell transplantation for MDS.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.Transplantation for myelodysplastic syndromes 2013.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge.Hematopoietic Cell Transplantation for Older Patients with MDS.Reduced-intensity conditioned allogeneic SCT in adults with AML.Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience.Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis.Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.

P2860

Q26799609-07A76E15-FBA8-4D9E-AD11-545507F95B8F Q33886907-F1B362BC-A715-48BD-A172-FBBA000F6C7A Q33917170-B2366E3C-2094-4D2F-997F-7BFF04DBF40A Q34260505-E87A89D4-D7F5-45F8-AAF2-B000EA9F5479 Q35000581-517406BE-6C7B-4BA6-B3AC-59EA71057B54 Q35073850-5385CA7B-DAC6-4A8B-85C2-8EB041F73162 Q35193735-B7EAEC1C-45B2-4C61-A957-DF42B5C695CF Q35882830-7A1859E5-F54D-4A26-A51C-D3C7DB603FA1 Q36063049-0930D448-8C86-48B7-97AE-6D0C865E3B0D Q36339459-7E73AEB8-D9F5-42AA-A45D-0249D8DD7062 Q36431041-275BF3FE-F242-4EE2-9DD4-BB4210E35E7B Q36811828-13C8F4EA-77C9-44CB-9D01-38EBB1A1726B Q37419348-F34AEB02-F7EF-4CD2-9513-FA5A4596AC90 Q37600407-21280959-E094-431D-8760-EAE7992884FD Q37718826-D2AAE57F-B356-44B1-9848-59B2280C0A03 Q37863461-0DE72576-A56F-453D-AF8A-D325C0004C60 Q37905034-74D2D416-7909-4C7F-9A1C-03750158FF43 Q37964938-E3CFFE21-EB75-44F2-99B7-F5D6F34795E2 Q38060264-AF48D49A-542F-49B1-95EA-BA7E5916094C Q38095833-44E80E13-3026-4D99-A8A7-442F4A3596B6 Q38195065-C97E44AB-40E1-4B17-8A47-7B0C5D7C09D5 Q38252578-27F9530C-C248-4B6C-8581-648B84E35F1F Q38366632-04E6E446-32B9-4086-9D39-1BAC454F15AF Q38479720-007392BA-1710-4927-8DAB-95956806207D Q40070259-CF19751B-45E8-478E-B09F-7B338F106657 Q41621459-FE20E51F-55F8-4D32-8301-530D00DC4572 Q43692529-98996B26-7A72-4345-935C-F6CE1ADDA14C Q47724804-1B50215F-59B9-4A46-971F-FCB607AB39BC Q48106141-AB6B979B-092D-4C8F-B889-693CFC90E43B Q48148219-56CF0D7A-5300-4D21-9127-1A4367C5E0D4 Q48596388-5E599D68-2D49-4489-8FAB-BAA128E8ED71 Q50848271-E5C33ACD-11B0-4FBF-9CBB-88CED693DBF8 Q52647269-AC24425E-AF7F-453A-8842-5D72153A33A7

P2860

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

http://www.wikidata.org/entity/Q34284225

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Conditioning with treosulfan a ...... risk hematologic malignancies.

@ast

Conditioning with treosulfan a ...... risk hematologic malignancies.

@en

Conditioning with treosulfan a ...... risk hematologic malignancies.

@nl

type

label

Conditioning with treosulfan a ...... risk hematologic malignancies.

@ast

Conditioning with treosulfan a ...... risk hematologic malignancies.

@en

Conditioning with treosulfan a ...... risk hematologic malignancies.

@nl

prefLabel

Conditioning with treosulfan a ...... risk hematologic malignancies.

@ast

Conditioning with treosulfan a ...... risk hematologic malignancies.

@en

Conditioning with treosulfan a ...... risk hematologic malignancies.

@nl

P1433

Q34284225-7521AE46-D415-4F8E-95B5-399A3B314D0C

P1476

Q34284225-68956ECF-B187-44A4-B204-D4FC15DBEAFF

P2093

Q34284225-072D85BA-B1D5-457C-95D6-0E47AE378F5C

Q34284225-265D06BB-7FF2-48F7-B9B5-68741C7CA829

Q34284225-2DF08994-A175-45ED-84A8-E4D9124C7E0F

Q34284225-45C3B5DF-AC2C-4819-9689-A10EEFBC3E69

Q34284225-4A57CDD2-054D-4C4A-9F24-CCDBFF5E5762

Q34284225-571600D6-2ECE-47C7-A379-1BE4DEE52EAB

Q34284225-8CFB94A7-B970-4A1B-A575-6E7432A660B0

Q34284225-9BBE2D16-1C62-4A48-BD25-36A7EBFC250F

Q34284225-B929EDA1-D8F0-47F6-B20E-3745732AFD30

Q34284225-BBC033F6-0671-47EA-8CF6-0C47588065ED

P2860

Q34284225-007F2E36-2CC5-4684-A5F6-D9990E0FEB6C

Q34284225-0215CB0E-7520-4CF2-8671-2710403D17CA

Q34284225-08279808-111E-4B71-B354-EC764AF216A4

Q34284225-234CA7E0-6F53-4557-ABFC-64AA3E328E76

Q34284225-240DFF92-CBEF-4254-A0F5-CAFD2716453C

Q34284225-25FC60EC-14AC-4CE2-9497-F3BA1CB659A4

Q34284225-35DC9311-1791-461A-A179-FD18F53EC7E2

Q34284225-37FEB65F-7EE2-404C-B16D-A78D89AC6FD4

Q34284225-4591BAFB-2587-4385-A4EA-6B336D3D89A7

Q34284225-45D7B9C1-A970-4D34-8277-0D7F256B11A8

P304

Q34284225-7F25CF72-332A-4231-8659-FC4645C46529

P31

Q34284225-7245EADC-4232-4516-94A6-CEF47CBA99E0

P356

Q34284225-BA2058FA-3707-4287-A79D-089DF141D4A2

P433

Q34284225-37AA886F-BDB1-4CF4-94E2-5D7A04E8D1EB

P478

Q34284225-A75DDE26-86F9-42F6-AEBF-6FE2DE08BC14

P50

Q34284225-D27DD553-66A3-4B9B-BDEB-5D9BD9A036CC

Q34284225-F977F563-92C9-4FBA-8F8B-A8FAA58EC627

P577

Q34284225-F6BFF5A2-F7A3-4C1D-9822-B1A5ABA72E6A

P5875

Q34284225-B164769B-38CD-4BFB-909E-73CB7F6AEB69

P698

Q34284225-477F6FA5-4AAA-4B14-B2BE-68C8EB66ADF3

P932

Q34284225-87AC26BD-B80A-455D-BBEF-27B21427449D

P356

J.BBMT.2010.05.007

P1433

Biology of Blood and Marrow Transplantation

P1476

Conditioning with treosulfan a ...... risk hematologic malignancies.

@en

P2093

Ann E Woolfrey

http://www.w3.org/2001/XMLSchema#string

Antonio Bedalov

http://www.w3.org/2001/XMLSchema#string

Bart L Scott

http://www.w3.org/2001/XMLSchema#string

Brent L Wood

http://www.w3.org/2001/XMLSchema#string

Eileen J Sickle

http://www.w3.org/2001/XMLSchema#string

Eneida R Nemecek

http://www.w3.org/2001/XMLSchema#string

Jean E Sanders

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Katherine A Guthrie

http://www.w3.org/2001/XMLSchema#string

Kristine C Doney

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Part

Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group

International scoring system for evaluating prognosis in myelodysplastic syndromes

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.

Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

P304

341-350

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2010.05.007

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Frederick R. Appelbaum

Hans Joachim Deeg

P577

2010-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45504666

http://www.w3.org/2001/XMLSchema#string

P698

20685259

http://www.w3.org/2001/XMLSchema#string

P932

2974965

http://www.w3.org/2001/XMLSchema#string